FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes(Jan 10, 2013)

RARITAN, NJ, January 10, 2013 – Janssen Research & Development, LLC (Janssen) announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 – 5 to recommend approval for canagliflozin, proposed trade name INVOKANA™,
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news